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Bone remodeling is regulated by various neuronal
inputs, including sympathetic tone, which is known
to inhibit bone mass accrual. This aspect of sympa-
thetic nervous system function raises the prospect
that the other arm of the autonomic nervous system,
the parasympathetic nervous system, may also affect
bone remodeling. Here, we use various mutant
mouse strains, each lacking one of the muscarinic
receptors that mediate parasympathetic activity, to
show that the parasympathetic nervous system
acting through the M3 muscarinic receptor is a posi-
tive regulator of bone mass accrual, increasing
bone formation and decreasing bone resorption.
Gene expression studies, cell-specific gene deletion
experiments, and analysis of compound mutant
mice showed that the parasympathetic nervous
system favors bone mass accrual by acting centrally
and by decreasing the sympathetic tone. By showing
that both arms of the autonomic nervous system
affect bone remodeling, this study further under-
scores the importance of neuronal regulation of bone.
INTRODUCTION
Bone remodeling, the physiological function assuring renewal of
bone tissue, consists of a perpetual alternation between a
resorption phase and a phase of de novo bone formation (Rodan
and Martin, 2000). One of the many significant recent advances
in our understanding of the regulation of bone remodeling has
been the identification of its neuronal control, revealed when de-
ciphering the mechanisms whereby the adipocyte-derived
hormone leptin regulates bone mass (Ducy et al., 2000).
Intracerebroventricular infusion of leptin in wild-type (WT) or lep-
tin-deficient (ob/ob) mice before or after chemical lesioning of
hypothalamic neuronal populations, together with the analysis of
multiple cell-specificgenedeletionmousemodels, hasestablished
that leptin inhibits bone mass accrual by acting solely throughCeneuronal means (Shi et al., 2008). First, after binding to its receptor
on brainstemneurons, leptin inhibits synthesis and release of sero-
tonin (Yadav et al., 2009). Brain-derived serotonin then signals
through the Htr2c receptor present on ventromedial hypothalamic
(VMH) neurons. This signaling event triggers a decrease of the
activityof thesympatheticnervoussystem(SNS),aknownnegative
regulator of bone mass accrual acting through the b2 adrenergic
receptor (Adrb2) present on osteoblasts (Elefteriou et al., 2005;
Fu et al., 2005; Takeda et al., 2002). The crucial role of the SNS in
the regulationof bone remodelingbegs thequestionof thepossible
role that the other arm of the autonomic nervous system, the
parasympathetic nervous system (PNS), may have in this context.
The PNS originates frommedial medullary sites. Vagal efferent
innervations extend from the medulla to postganglionic nerves in
various locations in the body (Agostoni et al., 1957; Brodal,
1981). Themain neurotransmitter used by PNS endings is acetyl-
choline, which binds to a small family of G protein-coupled
receptors, the muscarinic acetylcholine receptors (Caulfield,
1993; Wess, 1996). Molecular cloning has identified five different
muscarinic receptors (MRs), which can be subdivided into two
major classes. The M1R, M3R, and M5R selectively couple to G
proteins of the Gq family, whereas the M2R and M4R preferen-
tially activate Gi/Go type of G proteins (Caulfield, 1993; Caulfield
and Birdsall, 1998; Wess, 1996).
In an effort to determine whether or not the PNS regulates
bone remodeling, we studied the bone phenotype of mice lack-
ing muscarinic receptors. Here, we show that, of the four recep-
tors tested, M3 receptor (M3R) is the only muscarinic receptor
subtype influencing bone remodeling. Furthermore, studies of
mutant mouse strains harboring cell-specific gene deletion
establish that the M3R fulfills this function through its neuronal
expression and by decreasing sympathetic activity. Thus, these
experiments reveal that the PNS is a positive regulator of bone
mass accrual and that, unlike the SNS, it acts through a neuronal
relay, not an osteoblast relay, to fulfill this function.
RESULTS AND DISCUSSION
Signaling through M3R Favors Bone Mass Accrual
To determinewhether signaling through the PNS affects bone re-
modeling in vivo, we studied various strains ofmutantmice, eachll Metabolism 11, 231–238, March 3, 2010 ª2010 Elsevier Inc. 231
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mediate acetylcholine signaling (Wess, 2004; Wess et al., 2007).
We performed histological and microcomputed tomography
(mCT) analyses of vertebrae and long bones in 6-, 12-, and 24-
week-old WT and mutant mice. As shown in Figures 1C–1E,
even when studied in relatively old mice (24 weeks of age), the
absence of either M1R, M2R, or M4R did not affect significantly
bone mass as measured histologically by the ratio of bone
volume over tissue volume (BV/TV). None of these three muta-
tions affected either bone formation or bone resorption parame-
ters (Figures 1C–1E). In contrast, femaleM3R
/mice, which are
slightly shorter than WT littermates (Figure S1A–S1C available
online) as previously reported (Matsui et al., 2000), displayed at
6, 12, and 24 weeks of age a low bonemass phenotype affecting
both the axial (vertebrae) and appendicular (long bones) skeleton
(Figures 1A, 1B and S1F), whereas cortical thickness was unaf-
fected (Figure S1G). The same low bone mass phenotype was
observed in male M3R
/ mice (data not shown). The rest of
the analysis was done in female WT and mutant mice.
To better understand the pathogenesis of this low bone mass
phenotype, we first asked whether it could be explained by
abnormalities in the levels of circulating hormones or growth
factors. As shown in Figure 1K, leptin serum levels were signifi-
cantly lower in M3R
/ than in WT littermates, an abnormality
that should increase bone mass and therefore could not explain
the low bone mass phenotype of the M3R
/ mice (Karsenty,
2006). In our hands, corticosterone serum levels were within
the normal range inM3R
/mice (Figure 1K) and therefore could
not account for their bone phenotype either. In contrast, serum
levels of growth hormone and of insulin-like growth factor 1
(IGF-1), a cytokine that may promote bone formation (Kawai
and Rosen, 2008), were decreased in M3R
/ mice (Figure 1K).
The low bone mass phenotype observed in M3R
/ mice did
not seem to be due primarily to this decrease in circulating levels
of growth hormone and IGF-1. Specifically, when M3R
/ mice
were treated (once daily s.c. injection of 2 mg for 8 weeks) with
CJC1295, a synthetic long-acting growth hormone-releasing
hormone analog that enhances growth hormone secretion and,
as a result, increases circulating levels of IGF-1 (Jette´ et al.,
2005), we observed, as expected, a normalization of their growth
hormone and IGF-1 serum levels (Figures 1L and 1M). However,
these CJC1295-treated M3R
/ mice remained osteopenic
(Figure 1N). These observations indicate that parasympathetic
signaling through the M3R affects bone mass accrual and thatFigure 1. The Parasympathetic Nervous System, Acting through M3 R
and Decreasing Bone Resorption
(A) Histological analyses of WT andM3R
/ vertebrae. Bonemass is measured as
(BV/TV, %) after Von Kossa/Van Gieson staining.
(B) mCT analyses of WT and M3R
/ proximal tibiae.
(C–E) Histomorphometric analyses of vertebrae of 24-week-old M1R
/ (C), M2
parameters: BFR, bone formation rate; N.Ob/B.Pm, number of osteoblasts per b
(F, G, and I) Histomorphometric analyses of WT and M3R
/ vertebrae.
(H) TUNEL assay of calvarial sections. The number of apoptotic cells per 0.16 m
(J) ELISA analysis of plasma levels of total deoxypyridinoline (DPD), a biomarker
(K) Serum levels of hormones or growth factors in WT and M3R
/ mice.
(L–N) ELISA analysis of serum growth hormone (L) and IGF-1 (M) levels and histom
and WT mice.
N.S., statistically nonsignificant. n = 6–10 for all other experiments. *p < 0.05 c
represent SEM.
Cethis occurs, for the most part, in a growth hormone- and
IGF-1-independent manner.
Decreased Bone Formation and Increased Bone
Resorption in M3R
/ Mice
We next performed histological and biochemical studies to
define the cellular bases of the low bone mass phenotype
observed in M3R
/ mice. Histomorphometry analyses of
vertebrae showed that the low bone mass phenotype ofM3R
/
mice was secondary to a decrease in bone formation parame-
ters, including bone formation rate and osteoblast numbers
(Figures 1F and 1G). Importantly, we did not observe any
increase in osteoblast apoptosis in M3R
/ bones (Figure 1H),
a feature usually observed when bone formation is hampered
by corticosterone (Weinstein et al., 1998). In addition, there
was also an increase in bone resorption parameters, such as
the surface covered by osteoclasts and an increase in the circu-
lating levels of total deoxypyridinoline, a degradation product of
collagen and a biomarker of bone resorption (Eyre et al., 1988), in
M3R
/mice (Figures 1I and 1J). Taken together, results of these
analyses showed that the PNS is a positive regulator of bone
mass accrual, affecting both the formation and resorption arms
of bone remodeling, and identified M3R as amuscarinic receptor
involved in this process.
M3R Is Expressed in Neurons Involved in the Control
of Bone Mass
Given the direct effect of sympathetic signaling on osteoblasts,
we next asked whether the PNS regulates bone mass accrual
by acting directly on bone cells or through a different mecha-
nism. As a first approach, we studied M3R expression.
As shown in Figures 2A and 2B,M3R expression in osteoblasts
was two to three orders of magnitude lower than in various
regions of the brain, or than in other peripheral tissues where
it is known to be expressed and functional (Matsui et al., 2000;
Yamada et al., 2001). Moreover, M3R expression in osteoblasts
was also three orders of magnitude lower than the expression
of Adrb2, the adrenergic receptor mediating sympathetic
signaling in osteoblasts (Takeda et al., 2002) (Figure 2C). In the
face of this rather weak expression of M3R in osteoblasts and
in an effort to explain the bone phenotype of the M3R
/ mice,
we then askedwhere in the nervous systemM3Rwas expressed.
In situ hybridization studies revealed that, in addition to its
previously described expression in the hippocampus, visualeceptor, Favors Bone Mass Accrual by Increasing Bone Formation
the ratio of mineralized trabecular bone volume (black) over total tissue volume
R/ (D), M4R
/ (E), and corresponding WT littermates. Histomorphometric
one perimeter; Oc.S/BS, osteoclast surface per bone surface.
m2 field was comparable between 3-week-old WT and M3R
/ mice.
of bone resorption, in M3R
/ mice.
orphometric analysis of vertebrae (N) of CJC1295- and vehicle-treatedM3R
/
omparing to WT group. Results are represented as mean ± SEM; error bars
ll Metabolism 11, 231–238, March 3, 2010 ª2010 Elsevier Inc. 233
Figure 2. Expression Pattern of M3R
(A and B) Gene expression by real-time quantitative PCR (qPCR) analysis. Comparison ofM3R expression between osteoblasts, various regions of the brain (A),
and several peripheral tissues (B).
(C) Gene expression of M1R, M2R, M3R, M4R, and M5R in osteoblasts compared to that of Adrb2. The osteoblasts used were primary osteoblast cultures with
5 day induction for differentiation.
(D and E) In situ mRNA hybridization analysis ofM3R expression in brain. Tph2 andDbh are the molecular markers of the Dorsal Raphe (DR) and Locus Coeruleus
(LC) nuclei respectively.
Error bars represent SEM.
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1988),M3R is also expressed in neurons of theDorsal Raphe (DR)
and Locus Coeruleus (LC) nuclei in brainstem (Figures 2D and
2E). The DR and LC cluster serotonergic neurons and noradren-
ergic neurons, respectively, two pathways affecting bone mass
accrual (Takeda et al., 2002; Yadav et al., 2009). In contrast,
we failed to detect any M3R expression in neurons of VMH, a
hypothalamic structure whose integrity is required for the regula-
tion of bone mass accrual (Takeda et al., 2002) (Figure S2A). We
also failed to detectM3R expression in sympathetic chain ganglia
(Figure S2B). In summary, these various studies of M3R expres-
sion indicated thatM3R expression in osteoblasts is barely above
the limit of detection of quantitative PCR, whereas it is expressed
in the brain structures regulating bone mass accrual. As a result,
they suggested that the PNS favors bone mass accrual through
an indirectmechanism, i.e., its expression in neurons, rather than
by acting directly on osteoblasts.
Neuronal-Specific, but Not Osteoblast-Specific,
Inactivation of M3R Results in a Low Bone Mass
To determine formally the cell type in which signaling through
M3R must occur to favor bone mass accrual, we relied on cell-
specific gene inactivation experiments in the mouse.
Crossing mice harboring a floxed allele ofM3R (Gautam et al.,
2006) with a1(I)Collagen-Cre mice, a transgenic mouse line234 Cell Metabolism 11, 231–238, March 3, 2010 ª2010 Elsevier Inc.expressing the Cre recombinase specifically in osteoblasts
(Dacquin et al., 2002), allowed us to generate M3Rosb
/ mice.
Southern blot analysis demonstrated that we had successfully
deleted M3R in osteoblasts of M3Rosb
/ mice, but not in other
tissues (Figure 3A). Study of M3Rosb
/ mice at 12 weeks of
age, a time point whenM3R
/mice are profoundly osteopenic,
failed to detect any change in bone mass, bone formation, or
bone resorption parameters (Figure 3B), indicating that, in the
conditions of this experiment, M3R does not regulate bone
mass through its expression in osteoblasts. This result is consis-
tent with the very weak expression of M3R in these cells and
also consistent with the fact that muscarinic receptor agonist
treatment of WT or M3R
/ osteoblasts does not affect their
ability to form nodules and to produce alkaline phosphatase
(Figures S3A and S3B).
Next, we asked whether a deletion ofM3R in all neurons would
affect bone mass by crossing Nestin-Cre transgenic mice
(Tronche et al., 1999) with floxed M3R mice. Southern blot anal-
ysis verified that we had effectively deleted M3R in neurons, but
not in other cell types (Figure 3C).M3Rneuron
/mice of either sex
showed, at 6 and 12 weeks of age, a low bone mass phenotype
of similar severity as the one observed in mice lackingM3R in all
cells (Figures 3D and 3E). These histological findings were
confirmed by mCT analysis (Figure 3F). That the phenotype of
M3R
/ and M3Rneuron
/ mice was of equal severity indicates
Figure 3. Neuronal Mediation of the Parasympathetic Regulation of Bone Mass Accrual by M3R
(A and C) Recombination efficiency of the M3R locus in various tissues/organs of osteoblast-specific (A) and neuron-specific M3R-deficient mice
(C) by Southern blot.
(B, D, and E) Histomorphometric analysis of female 12-week-oldM3Rosb
/ (B), 12-week-oldM3Rneuron
/ (D), 6-week-oldM3Rneuron
/ (E), and corresponding
control vertebrae.
(F) mCT analyses of 12-week-old female M3R
fl/fl and M3Rneuron
/ proximal tibiae. Tb.Th, trabecular thickness.
(G and H) Twenty-four hour food intake and energy expenditure assays of M3Rneuron
/ and M3R
fl/fl control mice.




N.S., statistically nonsignificant. n = 6–10 per group. *p < 0.05 comparing to WT group. Results are represented as mean ± SEM. Error bars represent SEM.
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Figure 4. Increased Sympathetic Activity in M3R
/ Mice Leads to Low Bone Mass
(A and B) ELISA assays of epinephrine content in urine of M3R
/ (A) and M3Rneuron
/ (B) as well as WT control mice.
(C and D) qPCR analysis of Tph2 mRNA expression (C) and HPLC measurement of serotonin level in brainstem of WT and M3R
/ mice.




n = 6–10 per group. *p < 0.05 comparing to WT group. Results are represented as mean ± SEM. Error bars represent SEM.
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occurs through a neuronal relay. As was the case in M3R
/
mice, this osteopenia was due to a decrease in bone formation
and an increase in bone resorption parameters. These results es-
tablished that M3R regulates bone mass through its neuronal,
and not osteoblast, expression. Remarkably, appetite, which
is low in M3R
/ mice (Figures S1D and S1E) (Yamada et al.,
2001), was unaffected in M3Rneuron
/ mice (Figures 3G and
3H). This may have at least two explanations. First, the parasym-
pathetic regulation of bone mass accrual may occur indepen-
dently of its regulation of energy metabolism. Second, the
deletion of M3R in neurons may not be complete but may be
large enough to affect bone mass without affecting appetite.
Consistent with this latter hypothesis, we should point out that
we observed the same discrepancy between the effect on
bone mass and appetite in a leptin signaling gain-of-function
mouse model (Shi et al., 2008).
M3Rneuron
/mice displayed, like theM3R
/mice, a decrease
in growth hormone and IGF-1 circulating levels, as previously
reported (Gautam et al., 2009). To determine whether this abnor-
mality explained their low bone mass phenotype, we treated
them with CJC-1295. Although this treatment normalized the
serum levels of growth hormone and IGF-1, the low bone mass
phenotype of M3Rneuron
/ mice was not rescued, indicating236 Cell Metabolism 11, 231–238, March 3, 2010 ª2010 Elsevier Inc.that this phenotype develops independently of the growth
hormone and IGF-1 abnormalities (Figures 3I–3K).
Parasympathetic Signaling Favors Bone Mass Accrual
by Inhibiting Sympathetic Activity
The neuronal mediation of the PNS regulation of bone mass
accrual, along with the expression pattern of M3R in the DR
nuclei, led us to ask whether the PNS regulates bone mass by
affecting synthesis and release of serotonin by brainstem neu-
rons. Tph2 expression was normal, however, in M3R
/ mice,
as was the serotonin brainstem content (Figures 4C and 4D).
These two lines of experimental evidence argue strongly against
a model whereby the PNS would regulate bone mass by
affecting serotonergic output.
M3R is also expressed in the noradrenergic neurons of the LC
nuclei in brainstem (Figure 2E), and activation of these neurons is
correlated with an increase of sympathetic activity, as measured
by an increase in plasma epinephrine levels (Crawley et al.,
1980). Thus, we tested whether signaling through M3R regulates
bone mass accrual by affecting the sympathetic tone. A first
experimental argument supporting this mode of action was
that urinary levels of epinephrine were elevated in both M3R
/
and M3Rneuron
/ mice (Figures 4A and 4B). A second experi-
mental argument relies on genetic epistasis (Cordell, 2002).
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thetic signaling through Adrb2 lie in the same genetic pathway,
one would expect that removing one allele of Adrb2 from
M3R
/ background should rescue the bone phenotype of the
latter mutant mice. Consistent with this hypothesis, M3R
/;
Adrb2+/ mice had normal bone mass, bone formation, and
bone resorption parameters (Figure 4E). That the low serum
levels of growth hormone and IGF-1 characterizing M3R
/
mice were not corrected in M3R
/;Adrb2+/ mice (Figure 4F)
added further support to the notion that the low bone mass
phenotype of the M3R
/ mice is not secondary to their low
serum levels of growth hormone and IGF-1. Thus, our results
suggest that the PNS favors bone mass accrual by inhibiting
the activity of the sympathetic nervous system.
In summary, we present here in vivo evidence that the PNS,
signaling through the M3R, is—unlike the SNS—a positive regu-
lator of bone mass. Although they highlight the importance of
M3R in the context of the PNS regulation of bone mass, our
results do not rule out that M5R, which was not tested here,
may contribute to the regulation of bone mass by the PNS. An
unexpected feature of the PNS regulation of bone mass accrual
is that it does not occur on osteoblasts but, rather, on neurons,
where it decreases sympathetic activity. The expression of
M3R in the LC, a brain structure necessary for sympathetic
output, and the decrease of epinephrine urinary contents in
both M3R
/ and M3Rneuron
/ mice all argue for a model
whereby the PNS would favor bone mass accrual by inhibiting
sympathetic activity.
More generally, these observations broaden the importance of
the autonomic regulation of bonemass and add further credence
to the neuronal regulation of bone remodeling. The PNS acts to
dampen the negative influence of the sympathetic tone on bone
mass; such a function is also observed in other physiological
systems, including cardiac and digestive activity among others
(Goldstein, 2001). Moreover and although it is difficult to
compare their influence, it is striking that both the LRP5/sero-
tonin-dependent and the leptin/sympathetic regulation of bone
mass accrual inhibit bone formation (Ducy et al., 2000; Yadav
et al., 2008). This observation raises the prospect that other









fl/fl, a1(I)Collagen-Cre, and Adrb2
+/
mice used in these studies have been reported previously (Chruscinski et al.,
1999; Dacquin et al., 2002; Gautam et al., 2006; Gomeza et al., 1999a,
1999b; Miyakawa et al., 2001; Yamada et al., 2001), and all are on C57BL/6J
background. Nestin-Cre transgenic mice (C57BL/6J background) were from
the Jackson Laboratory (Bar Harbor, MA).
Bone Histology, mCT Analysis, and TUNEL Assays
Static and dynamic histomorphometric analyses were performed on undecal-
cified vertebral column specimens (see Supplemental Experimental Proce-
dures). mCT analyses were performed on proximal tibiae using a microcom-
puted tomography system (see Supplemental Experimental Procedures).
TUNELassaywasperformedon 3-week-oldmice to evaluate in vivoosteoblast
apoptosis as per manufacturer’s instructions (In Situ Cell Death Detection Kit,
Roche Applied Science, Indianapolis, IN). Four pups per genotype were
analyzed, and ten calvarial sections were counted per animal.CeFood Intake, Energy Expenditure, and CJC-1295 Treatment
Twenty-four hour food intake was measured using metabolic cages (Nalge),
and energy expenditure was assessed by an indirect calorimetry method
using a six-chamber Oxymax system (Columbus Instruments) as previously
described (Shi et al., 2008). One-week-old M3R
/, M3Rneuron
/, and
their WT littermates were treated with once daily s.c. injection of 2 mg of
CJC-1295 for 8 weeks.
Bioassays
Serum levels of total DPD (Quidel), leptin (R&D System), growth hormone
(DSL), IGF-1 (DSL), and corticosterone (MP Biomedicals) were measured
using commercially available kits. Urinary epinephrine contents were mea-
sured in acidified spot urine samples by EIA (Bi-CAT kit, Alpco), and creatinine
(Quidel) was used to standardize between urine samples.
Molecular Studies
RNA isolation (Trizol, Invitrogen) and cDNA synthesis (Superscript III, Invitro-
gen) were performed as per manufacturer’s instructions. Real-time quantita-
tive PCR (qPCR) was performed on an MX3000 instrument (Stratagene, La
Jolla, CA) using primers from SABiosciences (Frederick, MD) and the Taq
SYBR Green supermix with ROX (Biorad, Hercules, CA). Expression levels
of the studied genes were normalized by b-actin levels. Southern blots were
performed using probe 3, as previously described (Gautam et al., 2006).
In situ mRNA hybridization was performed on 20 mm cryosections using
DIG-labeled riboprobe hybridizing at 68C (see Supplemental Experimental
Procedures).
Statistical Analyses
Statistical significance was assessed by unpaired Student’s two-tailed t test.
Values were considered statistically significant at p < 0.05.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at doi:10.1016/j.
cmet.2010.01.005.
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